Serum amyloid P component as a biomarker in mild cognitive impairment and Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 26, Issue 6, 2008, Pages 522-527

  Verwey, Nicolaas A ^a,b   Schuitemaker, Alie ^a   Van Der Flier, Wiesje M ^a   Mulder, Sandra D ^a   Mulder, Cees ^a   Hack, C Erik ^a   Scheltens, Philip ^a   Blankenstein, Marinus A ^a   Veerhuis, Robert ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; Mild cognitive impairment; Serum amyloid P component

Indexed keywords

BIOLOGICAL MARKER; SERUM AMYLOID P;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; RISK FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RISK FACTORS; SERUM AMYLOID P-COMPONENT;

EID: 57049154011     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178756     Document Type: Article

References (31)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
2. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
3. Visser PJ, Kester A, Jolles J, Verhey F: Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67:1201-1207.
4. Selkoe DJ: Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994;53:438-447.
5. Zhan SS, Veerhuis R, Kamphorst W, Eikelenboom P: Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Neurodegeneration 1995;4:291-297.
6. Emsley J, White HE, Ohara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP: Structure of pentameric human serum amyloid-P component. Nature 1994;367:338-345.
7. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, et al: Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994;91:5602-5606.
8. Kimura M, Arai H, Takahashi T, Iwamoto N: Amyloid-P-component-like immunoreactivity in beta/A4-immunoreactive deposits in Alzheimer-type dementia brains. J Neurol 1994;241:170-174.
9. Pepys MB, Dyck RF, Debeer FC, Kershaw M: Serum amyloid P component - Binding to amyloid fibrils and immunohistochemical staining in normal human tissues. Clin Sci 1980;58:17-18.
10. Hutchinson WL, Hohenester E, Pepys MB: Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol Med 2000;6:482-493.
11. Hamazaki H: Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide. Biochem Biophys Res Commun 1995;211:349-353.
12. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E: Amyloid P component. A critical review. Amyloid J Protein Folding Disord 1997;4:274-295.
13. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB: Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997;3:855-859.
14. Tennent GA, Lovat LB, Pepys MB: Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995; 92: 4299-4303.
15. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-259.
16. Rostagno A, Lashley T, Ng D, Meyerson J, Braendgaard H, Plant G, Bojsen-Moller M, Holton J, Frangione B, Revesz T, Ghiso J: Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease. J Neurol Sci 2007;257:88-96.
17. Veerhuis R, Boshuizen RS, Familian A: Amyloid associated proteins in Alzheimer's and prion disease. Curr Drug Targets CNS Neurol Disord 2005;4:235-248.
18. Familian A, Eikelenboom P, Veerhuis R: Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci Lett 2007;416:87-91.
19. Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P: Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol (Berl) 2003;105:135-144.
20. Urbanyi Z, Sass M, Laszy J, Takacs V, Gyertyan I, Pazmany T: Serum amyloid P component induces TUNEL-positive nuclei in rat brain after intrahippocampal administration. Brain Res 2007;1145:221-226.
21. Mulder C, Schoonenboom SN, Wahlund LO, Scheltens P, van Kamp GJ, Veerhuis R, Hack CE, Blomberg M, Schutgens RB, Eikelenboom P: CSF markers related to pathogenetic mechanisms in Alzheimer's disease. J Neural Transm 2002;109:1491-1498.
22. Nishiyama E, Iwamoto N, Kimura M, Arai H: Serum amyloid P component level in Alzheimer's disease. Dementia 1996;7:256-259.
23. Kimura M, Asada T, Uno M, Machida N, Kasuya K, Taniguchi Y, Fujita T, Nishiyama E, Iwamoto N, Arai H: Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett 1999;273:137-139.
24. Nybo M, Olsen H, Jeune B, Andersen-Ranberg K, Nielsen EH, Svehag SE: Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement Geriatr Cogn Disord 1998;9:126-129.
25. Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB: Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem Biophys Res Commun 1994;201:722-726.
26. Folstein MF, Folstein SE, McHugh PR: Mini-mental state. Practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
27. McKeith IG, Fairbairn AF, Perry RH, Thompson P: The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994;165:324-332.
28. Roman GC, Sachdev P, Royall DR, Bullock RA, Orgogozo JM, Lopez-Pousa S, Arizaga R, Wallin A: Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004;226:81-87.
29. Neary D, Snowden J: Fronto-temporal dementia: nosology, neuropsychology, and neuropathology. Brain Cogn 1996;31:176-187.
30. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E: Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-258.
31. McGeer EG, Yasojima K, Schwab C, McGeer PL: The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol Aging 2001;22:843-848.